
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems is viewed favorably because its 3Q26 results showed broad-based organic growth of 8.9% and EPS of $1.12, both above consensus, while management raised full-year 2026 revenue guidance to $1.635B–$1.642B and EPS guidance to $4.33–$4.37. The outlook is supported by strength in the higher-growth Therapeutic and OEM businesses, improving Vascular Intervention trends, and reiterated WRAPSODY sales of about $7M in 2026, which together offset softer Foundational areas. Despite gross margin pressure from raw materials and freight, operating margin expanded to 21.3%, free cash flow was $53M in 3Q26, and leverage remained manageable at 1.5x, giving the company flexibility to fund growth and tuck-in acquisitions.
Bears say
Merit Medical Systems is facing a negative fundamental setup because the bear case assumes revenue growth of 5% or lower, with recent acquisitions contributing less and unsuccessful new product launches undermining operating leverage. That combination would likely drive further operating margin contraction and below-consensus earnings, leaving the business more exposed to disappointment in its core Cardiovascular segment, which supplies most revenue. Additional downside comes from risks of worse than expected margin performance, weaker free cash flow, and slower growth in China, possibly due to tenders.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Merit Medical Systems (MMSI) Forecast
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares